Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDX-1017 in Healthy Volunteers and Alzheimer's Disease
NCT03298672Phase 1Completed
- Sponsor
- LeonaBio
- Start
- Oct 2017
- Primary completion
- Sep 2019
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing NDX-1017 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 20 days. Started Oct 2017; status: completed.
02
Drugs
fosgonimeton
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03298672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298672.